Document 0873
 DOCN  M9590873
 TI    Reprimun--an antibiotic with large spectrum and immunomodulatory
       properties.
 DT    9509
 AU    Paunescu E; Marius Nasta Institute of Pneumophthisiology, Bucharest.
 SO    Pneumoftiziologia. 1994 Jul-Dec;43(3-4):189-95. Unique Identifier :
       AIDSLINE MED/95284586
 AB    Reprimun contains an oxyminomethyl rifamycin-SV derivative as the active
       substance and has a large spectrum antibiotic activity, on Mycobacterium
       tuberculosis too. Reprimun also shows an inhibitory activity on viral
       and human lymphocyte reverse transcriptases, an antiproliferative effect
       on retrovirus, as well as a selective immunomodulator action at the
       level of TCD4+ lymphocyte. In animal, the toxicity tests demonstrated a
       good tolerance. In human subject, the drug is quite well tolerated: no
       severe adverse reactions were noted during and after its administration
       for 10-12 months. In man, Reprimun administration demonstrated a
       therapeutical effect in bacterial infections (tuberculosis included),
       sarcoidosis, immune thrombocytopenia, as well as in Kaposi's sarcoma.
       The drug is only for oral administration. It is well absorbed at the
       level of duodenum, achieving a repeated entero-hepatic circuit that
       provides a prolonged efficient concentration of Reprimun in blood serum.
       Like many other ansamycin derivatives, Reprimun can be given
       intermittently (e.g. twice or three times weekly). In case of
       antisarcoidosis therapy, Reprimun was applied with good results in 112
       supervised cases, including 37 failures of a prior cortisone treatment
       its administration could be of a high benefit in HIV serum positive
       persons in which it can prevent both tuberculosis and HIV infection
       developments.
 DE    Adjuvants, Immunologic/ADVERSE EFFECTS/CHEMISTRY/*PHARMACOLOGY/
       PHARMACOKINETICS/THERAPEUTIC USE  Animal  Bacteria/DRUG EFFECTS
       Comparative Study  Drug Evaluation  Human  Immunologic Diseases/DRUG
       THERAPY  Lethal Dose 50  Mice  Mice, Inbred BALB C  Rifamycins/ADVERSE
       EFFECTS/CHEMISTRY/*PHARMACOLOGY/  PHARMACOKINETICS/THERAPEUTIC USE
       Sarcoidosis, Pulmonary/DRUG THERAPY  T-Lymphocytes/DRUG
       EFFECTS/IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).